WebLate-breaking abstracts that are accepted will have until December 9, 2024, to finalize their results. o CONCLUSIONS: The conclusion should be no more than 2 or 3 sentences regarding the significance of the results in the context of the original objectives. Late-breaking abstracts that are accepted will have until December 9, 2024, to finalize WebNov 15, 2024 · Late-Breaking Abstract Submission Deadline: March 16, 2024, at 12:00 PM (Noon) (ET) Abstract Notification Sent to First Author: March 31, 2024 Abstract …
Frequently Asked Questions - SITC 2024
WebSep 27, 2024 · Late-Breaking Abstract Submission Deadline: November 15, 2024, at 12:00 PM (EST) Abstract Change/Withdrawal Deadline: December 2, 2024, at 12:00 PM (EST) First Author Responsibilities. Body. The First Author Must: Agree to the Confidentiality Policy on behalf of all parties involved with the abstract and communicate this policy to all involved ... WebThe deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 10, 2024. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed ... maudie and fox
Home SABCS 2024
WebThursday morning opened with a late-breaking abstract that showed—once again!—sometimes the best way to help patients is by doing less. Early results from a planned analysis in September 2024 were so promising that the National Cancer Institute (NCI) decided the results needed to be unveiled early and Dr. Kevin Kalinsky kicked off … WebSep 12, 2024 · Late-Breaking Abstract submission is open. September 12, 2024. Researchers and physician-scientists from more than 600 universities, research … WebApr 14, 2024 · Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) Cancer Research American Association for Cancer Research Skip to Main Content … maudie review new york times